Project Grant R01HL179683
Award Date 9/1/25
Completion Date 5/31/29
Dollars Obligated $730K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Phoenix, AZ 85004, USA
Similar Awards
- This $695,403.00 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop therapeutic approaches to improve lung microvascular integrity and inhibit the progression of pulmonary fibrosis. The key proposed activities include: Evaluating whether restoring microvascular integrity through nanoparticle gene therapy can inhibit lung fibrogenesis. Determining if transplantation of FOXF1+CKIT+ endothelial progenitor cells can...
- The Project Grant award of $564,121 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to develop peptide surface-functionalized lipid nanoparticles (PepLNPs) for pulmonary delivery that can reach airway basal cells and use base editing technology to correct specific CFTR gene mutations associated with cystic fibrosis. The goal is to achieve permanent correction of lung disease in cystic fibrosis patients through one-time,...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $106,391 to the University of Colorado-Denver to investigate the role of developmental dysanapsis in lung development over the lifespan in an experimental bronchopulmonary dysplasia (BPD) model. The research aims to determine whether intra-amniotic endotoxin causes persistent dysanaptic growth of the airways, distal parenchyma, and vasculature in BPD, and...
- This $721,826 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify molecular mechanisms regulating alveolar matrix fibroblast function and their role in supporting vascular capillary formation. The research is being conducted by Children's Hospital Medical Center in Cincinnati, Ohio to advance the understanding of alveolar septation and septal wall maturation, which is...
- This federal Project Grant award for $637,913, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research by the University of Southern California (USC) to investigate the role of "transitional alveolar epithelial cells" in lung development and regeneration. The goal is to better understand the mechanisms underlying the alveolar epithelial cell differentiation process during normal lung development, as...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $629,498 to The Trustees of the University of Pennsylvania (UEI GM1XX56LEP58) to conduct research aimed at deciphering the molecular mechanisms underlying pediatric interstitial lung disease (CHILD). The key objectives are to: Interrogate the anomalous development of the lung epithelium in CHILD by defining the impact of a specific SFTPC gene mutation on alveolar...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $594,583 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital of Philadelphia (CHOP) Research Institute. The grant supports research to investigate the mechanisms regulating the development, expansion, and decline of neonatal lung myofibroblasts and their role in alveologenesis. Key objectives include utilizing a novel murine model to study myofibroblast lineage, characterize...
- The University of Rochester was awarded a $226,101 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on pulmonary angioblasts and their role in vascular development. The project aims to leverage existing single-cell RNA sequencing data to uncover novel insights into the cellular characteristics and regulatory mechanisms governing pulmonary angioblasts, which are critical for vascular regeneration and the...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...